---
title: "Weekly Recap | SPDR S&P Biotech +0.33%, mixed tape within biotech"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299515632.md"
description: "SPDR S&P Biotech (XBI) rose 0.33% this week to close at $156.72, while the S&P 500 fell 0.08%, leaving XBI about 0.41 percentage points ahead of the benchmark. The week was choppy, with an intraweek range of 4.99%. The ETF started Monday by edging up to $157.60, pulled back to $154.03 on Tuesday, touched a weekly low of $152.50 on Wednesday, then rebounded to a weekly high of $160.33 on Thursday before easing to $156.72 on Friday. The close was slightly above the prior week’s $156.20."
datetime: "2026-09-19T07:01:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299515632.md)
  - [en](https://longbridge.com/en/news/299515632.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299515632.md)
generator: "portal-rs"
---

# Weekly Recap | SPDR S&P Biotech +0.33%, mixed tape within biotech

## The Week

SPDR S&P Biotech (XBI) rose 0.33% this week to close at $156.72, while the S&P 500 fell 0.08%, leaving XBI about 0.41 percentage points ahead of the benchmark. The week was choppy, with an intraweek range of 4.99%. The ETF started Monday by edging up to $157.60, pulled back to $154.03 on Tuesday, touched a weekly low of $152.50 on Wednesday, then rebounded to a weekly high of $160.33 on Thursday before easing to $156.72 on Friday. The close was slightly above the prior week’s $156.20.

## Key Events

The biotech complex was driven by a handful of names that matter to XBI’s passive basket. Moderna gained after Phase III melanoma success, and some call options jumped 381% in a single day. Natera reported a lung cancer MRD study linking Signatera results to three-year recurrence-free survival in 1,129 patients, and the stock rose 12.3% on the week. Twist Bioscience climbed 31.26% after a tie-up with Lilly’s TuneLab on AI-driven drug discovery, though BWS Financial kept a sell rating with a $45 target. Halozyme swung on plans for a $1.3 billion convertible bond offering, then hit a record high after pricing. Iovance Biotherapeutics was up 307% for the year, and Roivant Sciences wrapped up its annual meeting with governance approvals. The common thread was cancer diagnostics, vaccines and AI-enabled drug development.

## The Week Ahead

No XBI constituents report earnings next week, and the macro calendar is light. Tuesday brings the Richmond Fed manufacturing index, with a prior reading of 4. Thursday includes jobless claims, the current account balance and new home sales, with the annualised rate expected at 608,000 versus 607,000 prior. Any shift in rate-related sentiment could ripple into growth-sensitive assets.

## In Short

XBI eked out a weekly gain and outperformed the S&P 500, but the tape was two-sided. Cancer vaccines, liquid biopsy and AI-driven drug discovery drew attention, while Halozyme’s convertible issuance stirred volatility. The latest-session money flow snapshot shows small-lot money as a net buyer by a wide margin. With the 60-day range spanning $143.775 to $169.89, XBI sits near the middle of that band at $156.72. The next test is how macro data affects rate expectations and whether the week’s pipeline themes hold up.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

## Related News & Research

- [Marqeta (MQ) Expands With Square And Coinbase, Is The Stock Still Undervalued?](https://longbridge.com/en/news/302983307.md)
- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [AppLovin Corporation $APP Stock Purchased by Hedeker Wealth LLC](https://longbridge.com/en/news/303049441.md)
- [EULAV Asset Management Acquires 9,727 Shares of Moderna, Inc. $MRNA](https://longbridge.com/en/news/303047245.md)
- [Moderna, Inc. $MRNA Shares Sold by IFP Advisors Inc](https://longbridge.com/en/news/303041682.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**